ALK and non-small cell lung carcinoma: Recently, the treatment of ALK-driven diseases was successfully improved by the development of crizotinib, an ALK/c-MET/ROS inhibitor approved in 2011 for the treatment of locally advanced or metastatic ALK-positive NSCLC 18, and currently in clinical trials for a variety of other ALK-related diseases including ALCL.